Novel anti-obesity therapeutics, including dual and especially triple incretin-based co-agonists, have for the first time allowed obese individuals to achieve very promising results in body weight loss, which tend to be comparable to those after bariatric surgery procedures, without exposure to this invasive treatment. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.